• FDA approves avelumab-axitinib for frontline RCC

    Approval is based on phase 3 JAVELIN Renal 101 study.

  • NICE approves nivolumab with ipilimumab for renal cancer

    Nivolumab with ipilimumab approved for use within the Cancer Drugs Fund for untreated advanced renal cell carcinoma

  • Metastatic kidney cancer: frontline atezolizumab-bevacizumab tops sunitinib in phase 3

    Data from IMmotion151.

  • FDA approves pembrolizumab-axitinib for renal cell carcinoma

    Approval is based on phase 3 KEYNOTE-426 study.

  • NICE decision on nivolumab with ipilimumab for renal cancer

    The treatment will be available within the Cancer Drugs Fund

  • Renal cancer: add-on dalantercept with axitinib fails phase 2 trial

    DART trial shows no PFS benefit in advanced clear-cell renal carcinoma.

  • Metastatic renal cancer: benefits of cytoreductive nephrectomy

    Survival benefit seen in patients with thrombus above the diaphragm.

  • mRCC: cabozantinib efficacy extends to non-clear-cell disease

    Real-world data fill the gaps left by clinical trials.

  • mRCC: frontline nivolumab+ipilimumab is cost-effective

    The combination added 0.96 QALY vs sunitinib.

  • aRCC: front-line avelumab-axitinib tops sunitinib in JAVELIN Renal 101

    Benefit observed regardless of risk group or PD-L1-positive status.

  • Advanced RCC: pembrolizumab-axitinib tops sunitinib in KEYNOTE-426

    Phase 3 trial shows survival advantage in front-line setting.

  • ASCO-GU 2019—Avelumab+axitinib bests sunitinib in previously untreated clear-cell aRCC

    Results from the ongoing JAVELIN Renal 101 phase 3 trial.

  • ASCO-GU 2019—Pembrolizumab+axitinib better than sunitinib in advanced or metastatic clear-cell RCC

    KEYNOTE-426 supports first-line treatment with pembrolizumab+axitinib as a new standard of care.

  • Large renal tumors: PN, RN yield similar CSS in meta-analysis

    Overall survival higher with partial nephrectomy.

  • RCC: nivolumab-ipilimumab yields QoL advantage in CheckMate-214

    Patient-reported outcomes consistently better vs sunitinib at 103 weeks.

  • Renal masses: 10-year data support RFA for tumors <3 cm

    Data show significantly poorer outcomes with larger tumors.

  • Immunotherapy equally effective in men, women with advanced cancer

    Meta-analysis of 23 RCTs involves over 13K patients.

  • Load more